Seroquel loss hits AstraZeneca
August 2, 2013Sales and Marketing AstraZeneca, Q2, Seroquel, symbicourt
Loss of exclusivity on brands such as the antipsychotic Seroquel IR helped put a $500 million dent in AstraZeneca’s performance …
Hill+Knowlton Strategies hires director
August 2, 2013Medical Communications Hill+Knowlton Strategies, hicks
Hill+Knowlton Strategies (H+K) has increased the size of its healthcare team with the appointment of Mary Hicks as a director. …
Targeted radiotherapy from 2018
August 2, 2013Sales and Marketing Cameron, NHS, proton beam
Proton beam therapy, a targeted form of radiotherapy, is to be available at hospitals in Manchester and London from 2018 …
Sanofi makes two new senior hires
August 2, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Sanofi
Sanofi has announced the appointments of Carsten Hellmann and David Meeker to its executive committee team. Hellmann (pictured) joins Sanofi …
Merck, Hedinger first suppliers certified under excipient scheme
August 1, 2013Manufacturing and Production Merck, Merck KGaA
Merck KGaA’s EMD Millipore unit and fellow German firm Hedinger have become the first two excipient suppliers to be certified …
Actelion to buy Ceptaris
August 1, 2013Sales and Marketing Actelion, FDA, ceptaris, valchlor
The US arm of Swiss speciality pharma group Actelion is in line to pay $250 million to buy private firm …
AstraZeneca signs $350m kidney deal
August 1, 2013Sales and Marketing AstraZeneca, CKD, fibrogen, kidney
AstraZeneca has signed a deal with private biotech company FibroGen to develop a novel compound aimed at treating anaemia associated …
Sanofi sales slide on patent cliff woes
August 1, 2013Sales and Marketing Aprovel, Plavix, Q2, Sanofi
Sanofi has been hit by generic erosion for key drugs in the second quarter, but the firm is confident it …
Internis hires Sandoz’ Paul Tredwell as COO
August 1, 2013Manufacturing and Production, Research and Development, Sales and Marketing Internis, Tredwell
Developer and supplier of bone disorder treatments Internis Pharmaceuticals has appointed Paul Tredwell as chief operating officer. Tredwell will report …
Pharma excipients ‘may affect gastrointestinal tract’, says study
July 31, 2013Manufacturing and Production Taylor, excipients
Excipients used in oral solid dosage forms are typically considered to be inert, but researchers in Japan have found they …
Lipitor competition holds Pfizer back
July 31, 2013Sales and Marketing Lipitor, Pfizer, Prevnar, Q2
Pfizer’s revenues in the second quarter of 2013 fell 7% year-on-year, in part due to the loss of patent in …
Merck sees sales dip
July 31, 2013Sales and Marketing Merck, Q2, Singulair, sales
A catastrophic decline in sales of asthma medicine Singulair is among the key reasons why Merck’s pharma revenue fell 12% …
UK life sciences gains £93 million backing
July 31, 2013Research and Development, Sales and Marketing BIA, DMD, life sciences
The UK life sciences sector has been given a new £93.2 million package of support by the government to help …
MHRA appoints three directors to its Board
July 31, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing DoH, MHRA
The Department of Health has announced that three new non-executive directors are joining the Medicines and Healthcare Products Regulatory Agency. …
BMS taps Samsung for antibody manufacturing
July 30, 2013Manufacturing and Production BMS, Samsung, antibody
Bristol-Myers Squibb has given signed a 10-year contract with South Korea’s Samsung BioLogics for the manufacture of one of its …
Adderall hits Shire sales
July 30, 2013Sales and Marketing Adderall, Shire, Vyvanse, ldx
Falling sales of Adderall XR have hit Shire in the second quarter of the year, with the ADHD drug dropping …
January deadline for Pfizer restructure
July 30, 2013Research and Development, Sales and Marketing Pfizer, patent, restructure
Pfizer is to restructure operations from January 2014 in a bid to make its business more responsive to patient and …
Nearly all UK men survive testicular cancer
July 30, 2013Research and Development, Sales and Marketing
Survival for testicular cancer has risen by almost 30% in the last 40 years, with nearly all men now beating …
Perrigo pays $8.6 billion for Elan
July 30, 2013Research and Development, Sales and Marketing Elan, Perrigo, Tysabri
Generics firm Perrigo has snapped up Ireland-based Elan in a multi-billion dollar deal, ending a bitter takeover battle that has …
Aesica appoints Chris Gowland to the Board
July 30, 2013Manufacturing and Production, Research and Development, Sales and Marketing Aesica, Chris Gowland
Contract development and manufacturing organisation Aesica has appointed Chris Gowland to the newly formed position of chief operating officer. As …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
